Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study

European Neuropsychopharmacology

Volumn 18, Issue 6, 2008, Pages 455-461

  Amiaz, Revital ^a   Fostick, Leah ^a   Gershon, Ari ^a   Zohar, Joseph ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Addiction; Augmentation; Naltrexone; Obsessive compulsive disorder; Opioid antagonist

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; NALTREXONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANAMNESIS; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPULSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HOSPITAL PATIENT; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTIVARIATE ANALYSIS OF VARIANCE; OBSESSIVE COMPULSIVE DISORDER; PATIENT INFORMATION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE DISORDER SCALE;

ADOLESCENT; ADULT; AGED; CLOMIPRAMINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NALTREXONE; NARCOTIC ANTAGONISTS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 42749090717     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.01.006     Document Type: Article

References (54)

1. Anton R.F. Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction 95 Suppl 2 (2000) S211-S217 Aug
2. Chappell P.B., Leckman J.F., Riddle M.A., Anderson G.M., Listwack S.J., Ort S.I., Hardin M.T., Scahill L.D., and Cohen D.J. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv. Neurol. 58 (1992) 253-262
3. Denys D., Zohar J., and Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry 65 Suppl 14 (2004) 11-17
4. Fineberg N.A., and Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 8 (2005) 107-129
5. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for the DSM-IV Axis I Disorders (1996), American Psychiatric Press, Washington
6. Friedman I., Dar R., and Shilony E. Compulsivity and obsessionality in opioid addiction. J. Nerv. Ment. Dis. 188 3 (2000) 155-162 Mar
7. Galarza N.J., Díaz Ramírez D., Guzmán F., Caballero J.A., and Martínez A.J. The use of naltrexone to treat ambulatory patients with alcohol dependence. Bol. Asoc. Med. P. R. 89 10-12 (1997) 157-160 Oct-Dec
8. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., and Crews F.T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 281 14 (1999) 1318-1325 Apr 14
9. Ginsberg D.L. Obsessive-compulsive disorder due to methadone discontinuation. Prim. Psychiatry 12 2 (2005) 25-26 Feb
10. Goldsmith T.B., Shapira N.A., and Keck Jr. P.E. Rapid remission of OCD with tramadol hydrochloride. Am. J. Psychiatry 156 4 (1999) 660-661 Apr
11. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch. Gen. Psychiatry 46 11 (1989) 1006-1011 Nov
12. Grant J.E., and Kim S.W. A case of kleptomania and compulsive sexual behavior treated with naltrexone. Ann. Clin. Psychiatry 13 4 (2001) 229-231
13. Grant J.E., and Kim S.W. An open-label study of naltrexone in the treatment of kleptomania. J. Clin. Psychiatry 63 4 (2002) 349-356
14. Guy W. Clinical global impressions ECDEU assessment manual for psychopharmacology. ECDEU: Natl. Inst. Health (1976) 218-222
15. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 32 (1959) 50-55
16. Hess C.W., Raymond D., Aguiar Pde C., Frucht S., Shriberg J., Heiman G.A., Kurlan R., Klein C., Bressman S.B., Ozelius L.J., and Saunders-Pullman R. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 68 7 (2007) 522-524 Feb 13
17. Hill S.Y., Muddasani S., Prasad K., Nutche J., Steinhauer S.R., Scanlon J., McDermott M., and Keshavan M. Cerebellar volume in offspring from multiplex alcohol dependence families. Biol. Psychiatry 61 1 (2007) 41-47 (Jan 1)
18. Hollander E., Kaplan A., Allen A., and Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr. Clin. North Am. 23 3 (2000) 643-656 Sep
19. Insel T.R., and Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am. J. Psychiatry 140 9 (1983)
20. Insel T.R., Mueller E.A., Alterman I., Linnoila M., and Murphy D.L. Obsessive-compulsive disorder and serotonin: is there a connection?. Biol. Psychiatry 20 11 (1985) 1174-1188 Nov
21. Keuler D.J., Altemus M., Michelson D., Greenberg B., and Murphy D.L. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol. Psychiatry 40 2 (1996) 154-156 Jul 15
22. Kim S.W. Opioid antagonists in the treatment of impulse-control disorders. J. Clin. Psychiatry 59 4 (1998) 159-164
23. Kim S.W., Grant J.E., Adson D.E., and Shin Y.C. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol. Psychiatry 49 11 (2001) 914-921
24. Kreek M.J. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann. N.Y. Acad. Sci. 909 (2000) 186-216
25. Koran L.M., Aboujaoude E., Bullock K.D., Franz B., Gamel N., and Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 66 3 (2005) 353-359 Mar
26. Lee Y.K., Park S.W., Kim Y.K., Kim D.J., Jeong J., Myrick H., and Kim Y.H. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol. 40 4 (2005) 297-301 (Jul-Aug)
27. Lubman D.I., Yucel M., and Pantelis C. Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction 99 12 (2004) 1491-1502
28. Mangold D.L., Peyrot M., Giggey P., and Wand G.S. Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism. Neuropsychopharmacology 22 6 (2000) 595-607 Jun
29. McDougle C.J., Barr L.C., Goodman W.K., and Price L.H. Possible role of neuropeptides in obsessive compulsive disorder. Psychoneuroendocrinology 24 1 (1999) 1-24 Jan
30. Moak D.H., Anton R.F., and Latham P.K. Further validation of the Obsessive-Compulsive Drinking Scale (OCDS). Relationship to alcoholism severity. Am J Addict. 7 1 (1998) 14-23 Winter
31. Modell J.G., Glaser F.B., Cyr L., and Mountz J.M. Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcohol Clin. Exp. Res. 16 2 (1992) 272-274 Apr
32. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-438
33. Naranjo C.A., Tremblay L.K., and Busto U.E. The role for the brain reward system in depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 (2001) 781-823
34. Numberg H.G., Keith S.J., and Paxton M. Consideration of the relevance of ethological animal models of human repetitive behavioral spectrum disorders. Biol. Psychiatry 41 2 (1997) 226-229
35. Pallanti S., Hollander E., Bienstock C., Koran L., Leckman J., Marazziti D., Pato M., Stein D., Zohar J., and International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int. J. Neuropsychopharmacol. 5 2 (2002) 181-191 Jun
36. Pelchat M.L. Of human bondage: food craving, obsession, compulsion, and addiction. Physiol. Behav. 76 (2002) 347-352
37. Papageorgiou C., Rabavilas A., Liappas I., and Stefanis C. Do obsessive-compulsive patients and abstinent heroin addicts share a common psychophysiological mechanism?. Neuropsychobiology 47 1 (2003) 1-11
38. Pitman R.K. A cybernetic model of obsessive-compulsive psychopathology. Compr. Psychiatry 28 4 (1987) 334-343 Jul-Aug
39. Ridley R.M. The psychology of preservative and stereotyped behavior. Prog. Neurobiol. 44 2 (1994) 221-231 Oct
40. Roy B.F., Benkelfat C., Hill J.L., Pierce P.F., Dauphin M.M., Kelly T.M., Sunderland T., Weinberger D.R., and Breslin N. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol. Psychiatry 35 (1994) 335-344
41. Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette's syndrome. Int. J. Neurosci. 35 1-2 (1987) 93-94 Jul
42. Shapira N.A., Keck Jr. P.E., Goldsmith T.D., McConville B.J., Eis M., and McElroy S.L. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress. Anxiety 6 4 (1997) 170-173
43. Srisurapanont M., and Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 8 2 (2005) 267-280 Jun
44. Suzuki K., Muramatsu T., Takeda A., and Shirakura K. Co-occurrence of obsessive-compulsive personality traits in young and middle-aged Japanese alcohol-dependent men. Alcohol Clin. Exp. Res. 26 8 (2002) 1223-1227
45. Urraca N., Camarena B., Gomez-Caudillo L., Esmer M.C., and Nicolini H. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am. J. Med. Genet., B Neuropsychiatr. Genet. 127 1 (2004) 94-96
46. Verebey K., Kogan M.J., and Mule S.J. Phencyclidine-induced stereotype in rats: effects of methadone, apomorphine, and naloxone. Psychopharmacology (Berl) 75 1 (1981) 44-47
47. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49 11 (1992) 876-880 Nov
48. Warneke L. A possible new treatment approach to obsessive-compulsive disorder. Can. J. Psychiatry 6 42 (1997) 667-668 Aug
49. Weizman R., Gil-Ad I., Hermesh H., Munitz H., and Laron Z. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuropharmacol. 13 (1990) 297-302
50. Woods-Kettelberger A., Kongsamut S., Smith C.P., Winslow J.T., and Corbett R. Animal models with potential applications for screening compounds for the treatment of obsessive-compulsive disorder. Expert Opin. Investig. Drugs 6 10 (1997) 1369-1381 Oct
51. Zohar J., and Insel T.R. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol. Psychiatry 22 6 (1987) 667-687 Jun
52. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., and Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch. Gen. Psychiatry 44 11 (1987) 946-951 Nov
53. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., and Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch. Gen. Psychiatry 45 2 (1988) 167-172 Feb
54. Zohar J., Zohar-Kadouch R.C., and Kindler S. Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs 43 2 (1992) 210-218 Feb